These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32327163)

  • 1. Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France.
    Ghabri S; Binard A; Pers YM; Maunoury F; Caro JJ
    Value Health; 2020 Apr; 23(4):461-470. PubMed ID: 32327163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
    Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ
    J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars.
    Wu B; Song Y; Leng L; Bucala R; Lu LJ
    Clin Exp Rheumatol; 2015; 33(1):20-6. PubMed ID: 25438197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis.
    Peng K; Chan SCW; Wang Y; Cheng FWT; Yeung WWY; Jiao Y; Chan EWY; Wong ICK; Lau CS; Li X
    JAMA Netw Open; 2024 Jun; 7(6):e2418800. PubMed ID: 38922614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1268-1280. PubMed ID: 31663465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
    J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    Adv Ther; 2019 Jun; 36(6):1337-1357. PubMed ID: 31004324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients.
    Tian F; Li JY; Wen ZH; Luo XW; Deng L; Zhang L; He JY
    Medicine (Baltimore); 2019 Nov; 98(48):e17750. PubMed ID: 31770193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity.
    Prawjaeng J; Leelahavarong P; Budtarad N; Pilasant S; Chanjam C; Katchamart W; Narongroeknawin P; Kitumnuaypong T
    BMC Health Serv Res; 2023 May; 23(1):561. PubMed ID: 37259090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis.
    Patel D; Shelbaya A; Cheung R; Aggarwal J; Park SH; Coindreau J
    Adv Ther; 2019 Aug; 36(8):2086-2095. PubMed ID: 31148057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis.
    Alemao E; Johal S; Al MJ; Rutten-van Mölken M
    Value Health; 2018 Feb; 21(2):193-202. PubMed ID: 29477401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
    Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis.
    Tan C; Luo X; Li S; Yi L; Zeng X; Peng L; Qin S; Wang L; Wan X
    Clin Rheumatol; 2022 Jan; 41(1):63-73. PubMed ID: 34373933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis.
    Incerti D; Hernandez EJM; Tkacz J; Jansen JP; Collier D; Gharaibeh M; Moore-Schiltz L; Stolshek BS
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1236-1242. PubMed ID: 32996384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate.
    Stevenson MD; Wailoo AJ; Tosh JC; Hernandez-Alava M; Gibson LA; Stevens JW; Archer RJ; Simpson EL; Hock ES; Young A; Scott DL
    J Rheumatol; 2017 Jul; 44(7):973-980. PubMed ID: 28202743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy.
    Diamantopoulos A; Benucci M; Capri S; Berger W; Wintfeld N; Giuliani G; Ricciardi W
    J Med Econ; 2012; 15(3):576-85. PubMed ID: 22313326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.
    Bansback NJ; Brennan A; Ghatnekar O
    Ann Rheum Dis; 2005 Jul; 64(7):995-1002. PubMed ID: 15550533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.